Breast Cancer

The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.

Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease).

Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.

To honor our connection to the field of breast cancer, we dedicate a special annual edition of JONS to breast cancer and the strides being made in the treatment of this disease as part of our Best Practices series.

A breast cancer diagnosis can be difficult for women of any age, but young women can have unique needs that make this experience more complex.

A breast nurse navigator can perform patient-centered education on breast cancer type and possible treatment options using the inclusive pathology report, as well as be available during the disease trajectory to proactively guide the patient with additional education and support.

A case study describing the course and outcomes of treatment, the real-life challenges that arise when attempting to utilize a manualized treatment, and the unique factors that contribute to this case.

Dr Chloe Grimmett presented findings from a pilot study on a web-based support tool for young breast cancer patients considering genetic testing for BRCA1/2.

The authors present their findings from a study aiming to determine the relationships of anxiety, social desirability, and demographics with group cohesion within a group intervention for African American breast cancer survivors.

The PARP inhibitor olaparib significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline BRCA mutation. Disease progression was delayed by about 3 months with olaparib in the multinational, randomized, open-label phase 3 study known as OlympiAD, reported Mark E. Robson, MD, at the 2017 ASCO Annual Meeting.